Inactive Instrument

Funds and ETFs ImmunoGen, Inc.




Biotechnology & Medical Research

Market Closed - Nasdaq 5-day change 1st Jan Change
31.23 USD 0.00% Intraday chart for ImmunoGen, Inc. +6.73% +5.33%
ImmunoGen, Inc. is a commercial-stage biotechnology company. The Company is focused on developing and commercializing of antibody- drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its ELAHERE (Mirvetuximab Soravtansine) is a first-in-class ADC targeting folate receptor alpha (FRa), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Its Pivekimab sunirine (PVEK), is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. The Company is advancing PVEK in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).
Related indices
More about the company
  1. Stock Market
  2. Equities
  3. IMGN Stock
  4. Funds and ETFs ImmunoGen, Inc.